Literature DB >> 28029320

Pulmonary Infiltrates in a Patient With Advanced Melanoma.

Charles A Powell1.   

Abstract

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 60-year-old former smoker with metastatic melanoma presented with the chief complaint of pulmonary infiltrates. Five years ago, he was diagnosed with a left chest wall melanoma. He underwent surgery but received no additional therapy for an American Joint Committee on Cancer stage T3a N0 M0 tumor that was 2.7 mm in depth with no ulceration of the epidermal surface. Resection margins were free of tumor. Four years later, he underwent excision of a raised pigmented skin lesion on his left calf that proved to be melanoma with positive margins. He underwent re-excision of melanoma but 2 months later developed a new left hip soft tissue nodule. Positron emission tomography (PET) -computed tomography showed multiple hypermetabolic lesions involving subcutaneous tissue, muscle osseous structures, and bone marrow, consistent with advanced melanoma. He began systemic therapy with ipilimumab and nivolumab. After four cycles of immunotherapy, he developed a nonproductive cough and mild dyspnea on exertion (Modified Medical Research Council dyspnea scale score of 2 [ie, he had to stop for breath when walking at his own pace on level ground]). A chest x-ray showed bilateral hilar enlargement, thickening of the right paratracheal stripe, and scattered patchy increased interstitial markings bilaterally. PET and chest computed tomography images showed enlarged mediastinal adenopathy with increased [18F]fluorodeoxyglucose uptake on PET and scattered diffuse 1- to 2-mm pulmonary nodules with ground-glass opacities ( Fig 1 ). The patient was referred for pulmonary input. The patient had smoked one pack of cigarettes per day for 35 years; he quit 6 years ago. He had no history of pneumonia, childhood asthma, or tuberculosis. His mother had asthma, but there was no other family history of asthma or other lung disease.

Entities:  

Mesh:

Year:  2016        PMID: 28029320     DOI: 10.1200/JCO.2016.69.9793

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  4 in total

1.  Microradiopharmaceutical for Metastatic Melanoma.

Authors:  Thiago Goulart Rosa; Sofia Nascimento Dos Santos; Terezina de Jesus Andreoli Pinto; Daniele Dal Molim Ghisleni; Thereza Christina Barja-Fidalgo; Eduardo Ricci-Junior; Mohammed Al-Qahtani; Jan Kozempel; Emerson Soares Bernardes; Ralph Santos-Oliveira
Journal:  Pharm Res       Date:  2017-10-23       Impact factor: 4.200

Review 2.  Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Authors:  Mizuki Nishino; Hiroto Hatabu; Lynette M Sholl; Nikhil H Ramaiya
Journal:  Radiographics       Date:  2017 Sep-Oct       Impact factor: 5.333

Review 3.  Clinical Management of Pneumonitis in Patients Receiving Anti-PD-1/PD-L1 Therapy.

Authors:  Justin E Bala-Hampton; Angela F Bazzell; Joyce E Dains
Journal:  J Adv Pract Oncol       Date:  2018-05-01

4.  Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series.

Authors:  Padmastuti Akella; Sundaravadivel Loganathan; Vishal Jindal; Jamal Akhtar; Amos Lal
Journal:  Respir Med Case Rep       Date:  2018-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.